Siplizumab

• CAT Number: I041836
• CAS Number: 288392-69-8
• Purity: ≥95%

Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody against CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enriches naïve and bona fide regulatory T cells[1].
Siplizumab (MEDI-507; 0.00001-10 nM) binds to FcγR and induces signal transduction[1].
Siplizumab (0.0001-10 μg/mL) mediates cell depletion and decreased T cell proliferation[1].

Reference

[1]. Binder C, et, al. Siplizumab, an Anti-CD2 Monoclonal Antibody, Induces a Unique Set of Immune Modulatory Effects Compared to Alemtuzumab and Rabbit Anti-Thymocyte Globulin In Vitro. Front Immunol. 2020 Nov 11;11:592553.
 [Content Brief]